

Consistently High 5.5-Year Progression-Free Survival Rates in Patients With and Without Bulky Baseline Lymphadenopathy ≥ 5 cm Are Associated With High Undetectable Minimal Residual Disease Rates After First-Line Treatment With Fixed-Duration Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Phase 2 CAPTIVATE Study

William G. Wierda, MD, PhD,¹ Ryan Jacobs, MD,² Paul M. Barry, MD,³ John N. Allan, MD,⁴ Tanya Siddiqui, MD,⁵ Alessandra Tedeschi, MD,⁶ Thomas J. Kipps, MD, PhD,⁷ Susan M. O'Brien, MD,⁸ Xavier O. Badoux, MIBBS, FRACP, FRCPA,⁹ Andrea Vescini, MD, PhD,¹⁰ Masa Iwasa, MIBBS, BMedSci, FRACP, FRCPA,¹¹ Dennis A. Carney, MIBBS, FRACP, FRCPA, PhD,¹² Anna Elinder Gamber, MIBBS, FRACP, FRCPA,¹³ Javier de la Serna, MD, PhD,¹⁴ Edin Szafer-Guzman, PhD,¹⁵ Cathy Zhou, MS,¹⁶ Jutta K. Neuenburg, MD, PhD,¹⁷ Lynne Neumann, MD,¹⁸ Anita Szoke, MD,¹⁹ James P. Dean, MD, PhD,²⁰ Paolo Ghia, MD, PhD,²¹ Constantine S. Tam, MIBBS, MD²²

¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²Levine Cancer Institute, Charlotte, NC, USA; ³Winnick Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; ⁴Weill Cornell Medicine, New York, NY, USA; ⁵City of Hope National Medical Center, Duarte, CA, USA; ⁶Regina Elena Hospital, Rome, Italy; ⁷University of California San Diego Moores Cancer Center, La Jolla, CA, USA; ⁸UC Irvine, Chao Family Comprehensive Cancer Center, Orange, CA, USA; ⁹Ministry of Health, Fogarini, NSW, Australia; ¹⁰University of Padua, Padua, Italy; ¹¹St Vincent's Hospital Melbourne, Melbourne, VIC, Australia; ¹²Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; ¹³North Shore Hospital, Auckland, New Zealand; ¹⁴Hospital Universitario 12 de Octubre, Madrid, Spain; ¹⁵AbbVie, North Chicago, IL, USA; ¹⁶Università Vita-Salute San Raffaele, Milan, Italy; ¹⁷IRCCS Ospedale San Raffaele, Milan, Italy; ¹⁸Alfred Hospital and Monash University, Melbourne, VIC, Australia

SUPPLEMENTAL INFORMATION

Baseline Characteristics According to Presence or Absence of Bulky Lymphadenopathy at Baseline (Longest Diameter < 5 cm vs ≥ 5 cm)

Characteristic	Baseline LDi < 5 cm n=136	Baseline LDi ≥ 5 cm n=66	Total N=202
Median age (range), years	59.5 (33–71)	60.0 (39–69)	60.0 (33–71)
Sex, n (%)			
Male	82 (60)	49 (74)	131 (65)
Female	54 (40)	17 (26)	71 (35)
Rai stage III/IV, n (%)	40 (29)	19 (29)	59 (29)
High-risk genomic features, n (%)			
Unmutated IGHV	73 (54)	46 (70)	119 (59)
del(17p)/mutated TP53 ^a	24 (18)	5 (8)	29 (14)
del(17p)	18 (13)	3 (5)	21 (10)
del(11q) ^b	19 (14)	17 (26)	36 (18)
Complex karyotype ^c	21 (15)	14 (21)	35 (17)
Any cytopenia	47 (35)	26 (39)	73 (36)
ANC $\leq 1.5 \times 10^9/L$	12 (9)	6 (9)	18 (9)
Hemoglobin ≤ 11 g/dL	33 (24)	18 (27)	51 (25)
Platelet count $\leq 100 \times 10^9/L$	16 (12)	9 (14)	25 (12)
Median ALC $\times 10^9/L$ (range)	65.0 (1–503)	62.8 (1–429)	64.4 (1–503)
ALC $\geq 25 \times 10^9/L$, n (%)	106 (78)	46 (70)	152 (75)


ALC, absolute lymphocyte count; ANC, absolute neutrophil count.

^adel(17p)/TP53 status was missing for 4 patients.

^bWithout del(17p) per Döhner hierarchy.

^cDefined as ≥ 3 abnormalities by conventional CpG-stimulated cytogenetics; complex karyotype status was missing for 30 patients.


EOT uMRD4 Rates According to EOT Residual Lymph Node Longest Diameter (LDi ≤ 1.5 cm, ≤ 2 cm, or > 2 cm)



EOT, end of treatment; LDi, lymph node long diameter; uMRD4, undetectable minimal residual disease $< 10^{-4}$ (by 8-color flow cytometry).


^aAssessed in evaluable patients with non-missing data at EOT.

Long-Term PFS Impact of Combined EOT Bone Marrow MRD Status and Residual Lymph Node Longest Diameter (LDi ≤ 1.5 cm, > 1.5 to ≤ 2 cm, > 2 cm)



dMRD, detectable MRD; PFS, progression-free survival.

EOT Bone Marrow MRD Status Is More Predictive Than iwCLL Response for Long-Term PFS



CR, complete response; CRi, complete response with incomplete bone marrow recovery; iwCLL, International Working Group on Chronic Lymphocytic Leukemia; nPR, nodular partial response; PR, partial response.